{"id":650051,"date":"2023-05-02T17:18:01","date_gmt":"2023-05-02T17:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=650051"},"modified":"2023-05-02T17:18:01","modified_gmt":"2023-05-02T17:18:01","slug":"multiple-myeloma-market-analysis-market-size-epidemiology-leading-companies-companies-bms-astrazeneca-pfizer-array-biopharma-biolinerx-morphosys-ag-imab-biopharma-chipscreen-biosciences","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-myeloma-market-analysis-market-size-epidemiology-leading-companies-companies-bms-astrazeneca-pfizer-array-biopharma-biolinerx-morphosys-ag-imab-biopharma-chipscreen-biosciences_650051.html","title":{"rendered":"Multiple Myeloma Market Analysis, Market Size, Epidemiology, Leading Companies | Companies – BMS, AstraZeneca, Pfizer, Array Biopharma, BioLineRx, MorphoSys AG, I-Mab Biopharma, Chipscreen Biosciences"},"content":{"rendered":"
\n
\"Multiple<\/a><\/div>\n
\n
Multiple Myeloma Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast\u20142032\u2019 report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.<\/div>\n

DelveInsight has launched a new report on”Multiple Myeloma – Market Insights, Epidemiology, and Market Forecast-2032”.<\/p>\n

DelveInsight’s “Multiple Myeloma – Market Insights, Epidemiology, and Market Forecast-2032″<\/a>report deliver an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Multiple Myeloma Market Report<\/a>:<\/p>\n

    \n
  1. In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM and the United States, in 2020, accounted for 32,270 cases (the highest number) which might increase in the forecast period.<\/li>\n
  2. In the 8MM, the total gender-specific cases of Multiple Myeloma were 43,910 cases for males and 36,805 cases for females in the year 2020 <\/li>\n
  3. According to DelveInsight’s analysis, in the 8MM, China reported the second-highest incident cases of Multiple myeloma, i.e., 21,116 which accounted for nearly 23% of the total 8MM cases, in the year 2020. <\/li>\n<\/ol>\n

    Key benefits of the report:<\/p>\n

      \n
    1. Multiple Myeloma  market report covers a descriptive overview and comprehensive insight of the Multiple Myeloma  epidemiology and Multiple Myeloma  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. The Multiple Myeloma market report provides insights on the current and emerging therapies.<\/li>\n
    3. Multiple Myeloma market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n
    4. The Multiple Myeloma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market.<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Multiple Myeloma Market Landscape.<\/a><\/p>\n

      Multiple Myeloma Overview<\/p>\n

      Multiple Myeloma is a sort of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with Multiple Myeloma, but joint problems can sometimes begin before skin patches appear.<\/p>\n

      The key players involved in the Multiple Myeloma market<\/a>:<\/p>\n

        \n
      1. Cartesian Therapeutics, <\/li>\n
      2. AbbVie, and Roche, <\/li>\n
      3. Janssen, <\/li>\n
      4. Biotech\/Nanjing Legend Biotech, <\/li>\n
      5. Merck Sharp & Dohme Corp., <\/li>\n
      6. Janssen Research & Development, <\/li>\n
      7. Regeneron Pharmaceuticals, <\/li>\n
      8. Bristol-Myers Squibb\/Celgene, <\/li>\n
      9. BMS\/ AstraZeneca, <\/li>\n
      10. Pfizer (Array Biopharma), <\/li>\n
      11. BioLineRx, <\/li>\n
      12. MorphoSys AG\/I-Mab Biopharma, <\/li>\n
      13. Chipscreen Biosciences,<\/li>\n
      14. And others.<\/li>\n<\/ol>\n

        The launch of the emerging therapies is expected to significantly impact the Multiple Myeloma treatment scenario<\/a> in the upcoming years:-<\/p>\n

        Drug covered<\/p>\n

          \n
        1. Descartes-11, <\/li>\n
        2. Venetoclax,  <\/li>\n
        3. Ciltacabtagene Autoleucel (cilta-cel\/ JNJ-68284528\/LCAR-B38M), <\/li>\n
        4. Keytruda (Pembrolizumab), <\/li>\n
        5. Cetrelimab (JNJ-63723283), <\/li>\n
        6. REGN5458, <\/li>\n
        7. Iberdomide, <\/li>\n
        8. Imfinzi (Durvalumab; MEDI4736), <\/li>\n
        9. Braftovi (encorafenib),  <\/li>\n
        10. Motixafortide (BL-8040), <\/li>\n
        11. Felzartamab (MOR202), <\/li>\n
        12. Chidamide (Epidaza),<\/li>\n
        13. And others.<\/li>\n<\/ol>\n

          Table of Contents<\/p>\n

          1. Report Introduction<\/p>\n

          2. Executive Summary<\/p>\n

          3. SWOT analysis<\/p>\n

          4. Multiple Myeloma  Patient Share (%) Overview at a Glance<\/p>\n

          5. Multiple Myeloma  Market Overview at a Glance<\/p>\n

          6. Multiple Myeloma  Disease Background and Overview<\/p>\n

          7. Multiple Myeloma  Epidemiology and Patient Population<\/p>\n

          8. Country-Specific Patient Population of Multiple Myeloma <\/p>\n

          9. Multiple Myeloma  Current Treatment and Medical Practices<\/p>\n

          10. Unmet Needs<\/p>\n

          11. Multiple Myeloma  Emerging Therapies<\/p>\n

          12. Multiple Myeloma  Market Outlook<\/p>\n

          13. Country-Wise Multiple Myeloma  Market Analysis (2019–2032)<\/p>\n

          14. Market Access and Reimbursement of Therapies<\/p>\n

          15. Market drivers<\/p>\n

          16. Market barriers<\/p>\n

          17. Appendix<\/p>\n

          18. Multiple Myeloma  Report Methodology<\/p>\n

          19. DelveInsight Capabilities<\/p>\n

          20. Disclaimer<\/p>\n

          21. About DelveInsight<\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           DelveInsight Business Research LLP<\/a>
          Contact Person:<\/strong> Kritika Rehani
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 9193216187
          Address:<\/strong>304 S. Jones Blvd #2432
          City:<\/strong> Las Vegas
          State:<\/strong> Nevada
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.delveinsight.com\/<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          Multiple Myeloma Market DelveInsight\u2019s \u2018Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast\u20142032\u2019 report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-650051","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=650051"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650051\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=650051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=650051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=650051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}